Processa Pharmaceuticals Files 8-K
Ticker: PCSA · Form: 8-K · Filed: Jul 25, 2025 · CIK: 1533743
| Field | Detail |
|---|---|
| Company | Processa Pharmaceuticals, Inc. (PCSA) |
| Form Type | 8-K |
| Filed Date | Jul 25, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, SEC filing, financials
TL;DR
Processa Pharma filed an 8-K on 7/25/25 for other events and financials.
AI Summary
On July 25, 2025, Processa Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating updates or disclosures related to the company's financial status and significant occurrences. No specific financial figures or new events were detailed in the provided excerpt.
Why It Matters
This filing signals that Processa Pharmaceuticals is providing updated information to the SEC, which could include material events or financial disclosures relevant to investors.
Risk Assessment
Risk Level: low — The filing is a routine disclosure and does not contain information indicating immediate or significant risk.
Key Players & Entities
- Processa Pharmaceuticals, Inc. (company) — Registrant
- July 25, 2025 (date) — Date of earliest event reported
- 001-39531 (other) — Commission file number
- Delaware (other) — State of incorporation
- 45-1539785 (other) — I.R.S. Employer Identification Number
- 601 21st Street, Suite 300, Vero Beach, FL 32960 (address) — Principal Executive Offices
- (772) 453-2899 (phone_number) — Registrant's Telephone Number
FAQ
What specific "Other Events" are being reported by Processa Pharmaceuticals?
The provided excerpt of the 8-K filing does not detail the specific "Other Events" being reported, only that this is an item of information included in the filing.
What is the significance of filing "Financial Statements and Exhibits"?
Filing "Financial Statements and Exhibits" indicates that Processa Pharmaceuticals is providing updated financial information or relevant supporting documents to the SEC, as required.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on July 25, 2025.
What is Processa Pharmaceuticals' principal executive office address?
Processa Pharmaceuticals' principal executive office is located at 601 21st Street, Suite 300, Vero Beach, FL 32960.
What is the company's commission file number?
The company's commission file number is 001-39531.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 25, 2025 regarding Processa Pharmaceuticals, Inc. (PCSA).